Sanofi India Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rv0q0w9ia6a8haajdkqm2ll8.pdf

Key Takeaways


Domestic Performance & the NLEM Overhang

Hrosz: "We outlined this plan back at the end of 2022 and we continue to walk that talk. So this is what we said we would do. And we've been consistent in progressing against those four pillars."

Strategic Partnerships: CV to Emcure, CNS to Cipla

Hrosz: "It's not an un-licensing deal. It's a distribution and promotion deal."

Diabetes: Soliqua Entry & Portfolio Completion

Hrosz: "INR1,000 crores, which is the same size of the market where we compete with Lantus and Toujeo, right? It's a very large market where we don't compete. And we believe Soliqua has the strength to achieve leadership in that segment of premix."

Consumer Healthcare: Demerger & Building Blocks


India for India Plan & Local Innovation


Guidance & Commitments

CommitmentSpecificsTimeline
CHC listingDemerger completed, FMCH organization established, shares listedNext few months
Lantus volume expansionVolume growth to accelerate and be sustained for a prolonged period post-NLEM price reductionAlready visible, expected to sustain
Soliqua market leadershipAchieve leadership in the INR1,000 crores premix insulin segmentNo date; "coming months and years"
TZIL launchFirst-in-class type 1 diabetes therapy brought to Indian marketNo date given
Allegra launchNext innovation in the India for India plan, coming through the mergerPost-merger

Key Metrics

MetricQ1 FY24
Domestic retained sales₹566 cr, +3% YoY reported, +8% YoY excluding NLEM impact
Profit before exceptional items and tax₹215 cr, -12% YoY from ₹246 cr in Q1 FY23, double-digit growth QoQ from ₹189 cr in Q4 FY23
Profit before exceptional items and tax margin31%, compared to 36% in Q1 FY23 which was exceptional
Export growth (Q1 FY23)+30% YoY, driven by volume, favourable FX, and freight-related gross margin benefit
Exceptional items: gain on asset sale (Q1 FY23)~₹18 cr
Exceptional items: severance costs (Emcure/Cipla partnerships)~₹27 cr
Other income (Q1 FY23)~₹19 cr, from interest on bank deposits and income tax refund
Consumer Healthcare sales contribution~30% of total company sales, unaudited
Consumer Healthcare operating profit contribution37% to 39% of total, unaudited, could vary by 1 ppt
Basal insulin market share38%
Total insulin market share8% (per an analyst's math)
Premix insulin market size~₹1,000 cr
Basal insulin market size~₹1,000 cr
Employee count (FY23)~2,100, down from ~2,600 in FY22